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Objective: This study explored the safety and efﬁcacy of recombinant type I pancreatic elastase (PRT-201) topically applied
once to the external surface of an arteriovenous ﬁstula.
Methods: This was a randomized, double-blind, placebo-controlled trial. Adults with kidney disease undergoing creation
of a radiocephalic ﬁstula (RCF) or brachiocephalic ﬁstula were randomized to treatment with placebo (n[ 51), PRT-201
at 10 mg (n [ 51), or PRT-201 at 30 mg (n [ 49). The primary efﬁcacy measure was unassisted primary patency (PP)
over 1 year. Secondary efﬁcacy measures were secondary patency (SP), unassisted maturation by ultrasound interrogation,
use for hemodialysis, and hemodynamically signiﬁcant lumen stenosis.
Results: Median PP was 224 days for placebo and >365 days for the PRT-201 groups. At 1 year, 45%, 54%, and 53% of
placebo, 10-mg, and 30-mg patients retained PP. The risk of PP loss was nonsigniﬁcantly reduced for 10 mg (hazard ratio
[HR], 0.69; P[ .19) and 30 mg (HR, 0.67; P[ .17) vs placebo. In the subset (44% of patients) with a RCF, the median
PP was 125 days for placebo and >365 days for the PRT-201 groups. At 1 year, 31%, 50%, and 63% of placebo, 10-mg,
and 30-mg RCFs retained PP. The risk of RCF PP loss was nonsigniﬁcantly reduced by 10 mg (HR, 0.59; P [ .18) and
signiﬁcantly reduced by 30 mg (HR, 0.37; P [ .02) vs placebo. At 1 year, 77%, 81%, and 83% of placebo, 10-mg, and
30-mg patients retained SP. The risk of SP loss was nonsigniﬁcantly reduced for 10 mg (HR, 0.79; P [ .61) and 30 mg
(HR, 0.76; P [ .55) vs placebo. In the subset with RCFs, 65%, 82%, and 90% of placebo, 10-mg, and 30-mg patients
retained SP at 1 year. The risk of RCF SP loss was nonsigniﬁcantly reduced for 10 mg (HR, 0.45; P [ .19) and 30 mg
(HR, 0.27; P [ .08) vs placebo. At month 3, 67%, 87% (P [ .03), and 92% (P < .01) of the placebo, 10-mg, and 30-mg
group ﬁstulas had unassisted maturation by ultrasound interrogation. At month 3 in the subset with an RCF, 47%, 74%
(P [ .17), and 93% (P < .01) of placebo, 10-mg, and 30-mg group ﬁstulas had unassisted maturation by ultrasound
interrogation. Adverse event reports were not meaningfully different between groups.
Conclusions: PRT-201 appeared safe. The primary efﬁcacy end point was not met. However, both PRT-201 doses were
associated with improved unassisted maturation. The 30-mg dose was associated with increased PP in the subset with
RCF. (J Vasc Surg 2014;60:454-61.)An arteriovenous ﬁstula (AVF) is the most desirable
form of vascular access for hemodialysis, resulting in the
highest patency rate and the lowest complication rate.
Unfortunately, 40% to 60% of AVFs will lose unassisted
primary patency (PP) due to thrombosis or a procedure
to restore or maintain patency within the ﬁrst year after
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access.4,7,8
Porcine pancreatic elastase applied to the adventitia of
arteries and veins after vessel injury has been shown to
result in partial fragmentation of elastin and decreased neo-
intimal hyperplasia by inhibiting cell migration to the in-
tima, possibly due to the chemotactic properties of elastin
fragments within the adventitia.14,15 PRT-201 is a recom-
binant type I pancreatic elastase (molecular weight w26
kD) that is expressed in human skin but not the pancreas.16
PRT-201 is produced in the yeast Komagataella phafﬁi
(formerly Pichia pastoris).
PRT-201 and other pancreatic elastases are inactivated
by antiproteases present in blood, so to be effective, PRT-
201 must be applied to the outside of blood vessels.17 In
animal pharmacology and toxicology studies, PRT-201
fragmented and removed elastin ﬁbers from blood vessels
in a time-dependent and concentration-dependent man-
ner. In a phase 1 clinical trial, PRT-201 was applied topi-
cally to the external adventitial surface of newly created
AVFs. Doses (3, 10, and 33 mg) that fragment elastin ﬁbers
in the vein adventitia were associated with prolonged AVF
PP, fewer angioplasty procedures, and less AVF lumen ste-
nosis.18 These beneﬁts were not observed at higher doses
(100 mg to 9 mg) that fragment elastin ﬁbers in the vein
adventitia, media, and intima.
We report the ﬁndings of a phase 2 clinical study that
compared the safety and efﬁcacy of PRT-201 at 10 mg
and 30 mg vs placebo topically administered at the time
of AVF creation.
METHODS
Trial design. This was a randomized, double-blind,
placebo-controlled, study of a single application of PRT-
201. The protocol, informed consent form, and all amend-
ments were reviewed and approved by each center’s
Institutional ReviewBoard. A full list of participating centers
can be found in the Appendix (online only). This study was
conducted in accordance with the ethical principles origi-
nating from the Declaration of Helsinki and current Good
Clinical Practices and in compliance with the Code of
Federal Regulations (21 CFR 312). This trial was preregis-
tered at www.clinicaltrials.gov (Identiﬁer NCT01305824).
Participants. Patients were at least 18 years old with
chronic kidney disease and were receiving maintenance
hemodialysis or expecting to initiate maintenance hemodi-
alysis #6 months and undergoing the creation of a radio-
cephalic ﬁstula (RCF) or brachiocephalic ﬁstula (BCF).
Interventions. Immediately after creation of the AVF,
a 2.5-mL PRT-201 solution or placebo was topically
delivered as a series of drops over 10 minutes to the
exposed inﬂow artery, anastomosis, and outﬂow vein. Drug
application was followed by lavage of the wound with saline
for 1 minute. PRT-201 was supplied as a lyophilized pow-
der in 5-mg vials that was reconstituted with phosphate-
buffered saline with .01% polysorbate 80 and diluted to a
ﬁnal concentration of 4 or 12 mg/mL by an unblinded
research pharmacist. PRT-201 and placebo (phosphate-buffered saline) were identical in appearance; both are clear
nonviscous liquids that froth slightly if shaken.
Outcomes. Safety assessments and evaluation of the
AVF were performed at 2 and 6 weeks, and at 3, 6, 9,
and 12 months after study drug administration. Safety eval-
uations included ascertainment of adverse events, physical
examinations, duplex ultrasound imaging, and laboratory
studies. The primary efﬁcacy end point was PP. The sec-
ondary efﬁcacy end points included SP, unassisted matura-
tion by ultrasound interrogation, use for hemodialysis, and
hemodynamically signiﬁcant lumen stenosis. A loss of PP
was deﬁned as the ﬁrst occurrence of access thrombosis
or a procedure performed to restore or maintain AVF
patency (thrombectomy, thrombolysis, percutaneous trans-
luminal angioplasty, stent placement, or surgical revision).
A loss of SP was deﬁned as AVF abandonment (ie, decision
to place a new permanent access).
Duplex ultrasound imaging was performed at 6 weeks
and 3 months using a standard protocol. All ultrasound ex-
aminations were reviewed by an independent and experi-
enced core laboratory (VasCore, Boston, Mass) masked
to treatment assignment and outcome. The core laboratory
measured outﬂow vein lumen diameter and blood ﬂow rate
to assess maturation and the presence of hemodynamically
signiﬁcant stenosis in the AVF circuit.
Successful maturation was deﬁned using the National
Kidney Foundation (NKF) KidneyDiseaseOutcomesQual-
ity Initiative (KDOQI) criteria (average cephalic vein lumen
diameter $6 mm and an outﬂow vein blood ﬂow rate
$600 mL/min)9 and also separately using the criteria pub-
lishedbyRobbinet al19 (average cephalic vein lumendiameter
$4mmand an outﬂow vein blood ﬂow rate$500mL/min).
Unassisted maturation was deﬁned as maturation with no
prior procedure to restore or maintain patency.
Hemodynamically signiﬁcant stenosis was deﬁned as a
peak systolic velocity (PSV) ratio >2 in the inﬂow artery
or outﬂow vein, or a PSV ratio >3 with a minimum PSV
of 400 cm/s at the anastomosis. The PSV ratio was deter-
mined by dividing the PSV within the stenotic segment by
the PSV in an adjacent proximal normal segment. Stenosis
was categorized as being within or outside of the treatment
zone, which included the anastomosis, the adjacent 2 cm of
inﬂow artery, and the adjacent 5 cm of outﬂow vein. Re-
sults of the core laboratory interpretations were not shared
with the study team or treating clinicians.
Statistical methods. The study planned for 150 to be
randomly and equally allocated into one of three groups. It
was assumed that the proportion with PP at the end of the
study would be 50% in the placebo group and 80% in each
of the PRT-201-treated groups, corresponding to a hazard
ratio (HR) of 0.32. A two-sided, log-rank test at the a ¼
.05 level would have >80% power with 50 patients per
group to detect this treatment effect.
The full analysis set was deﬁned as all patients who
received any amount of study agent. This was the primary
analysis set for all analyses of efﬁcacy and safety. Patients
were analyzed according to the actual study drug received.
PP time was estimated by the 25th, 50th (median), and
Fig 1. Patient ﬂow through the study. PRT-201, Recombinant type I pancreatic elastase.
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test methods to estimate the survival functions. A log-rank
test was used to test the equality of the survival curves be-
tween each PRT-201 dose vs placebo. A similar analysis
was performed for SP. A proportional hazard model was
used to explore important baseline covariates of age, sex,
race, medical history (diabetes, vascular disease, hyperten-
sion, hypercholesterolemia, ischemic heart disease, periph-
eral artery disease, cardiovascular disease, renal transplant),
dialysis status (predialysis or receiving dialysis), AVF type
(RCF or BCF), type of anesthesia (general, local, nerve
block), exposed vein and arteriotomy lengths (longer or
shorter than median), and method of dilation (hydrostatic
or mechanical) to assess their effect on PP.
The numbers and percentages of patients achieving
assisted and unassisted maturation, assisted and unassisted
use of the AVF for hemodialysis, requiring procedures to
restore or maintain patency, and with hemodynamically sig-
niﬁcant stenosis were summarized. Each PRT-201 group vs
placebo was tested using a Pearson’s c2 test or the Fisher
exact test (cell size <5) as appropriate. A rate of procedures
to restore or maintain patency per person-year at risk wascalculated as the total number of procedures per person-
year on study. A Wilcoxon rank sum test was used to
compare treatment groups.
Several additional analyses were performed after database
lock. These included Kaplan-Meier analyses and Cox propor-
tional hazards modeling of time to loss of PP in a subgroup
omitting procedures directed at cephalic arch or central vein
stenosis and Kaplan-Meier analyses of time to PP and SP
loss, and procedure rates in the subgroups with RCF andBCF.
RESULTS
Participants. The study randomized 169 patients, and
151 were treated at 23 centers (range, 1-25 treated per
center). The reasons for nontreatment were an access pro-
cedure other than RCF or BCF (11 patients), withdrawn
consent (2 patients), enrollment closed (4 patients), and
ineligible medical history (recent renal cell carcinoma, 1 pa-
tient). Of the 151 patients who were treated, 127 (84%)
completed the study, and 24 (16%) discontinued before
completion (Fig 1).
Baseline data. Table I summarizes baseline charac-
teristics by treatment group. There were no signiﬁcant
Table I. Baseline characteristics by treatment group
Variable
Placebo
(n ¼ 51)
PRT-201
10 mg
(n ¼ 51)
30 mg
(n ¼ 49)
Male, % 63 55 55
White, % 63 78 74
Age, mean 6 SD, years 59 6 15 59 6 18 59 6 15
$65 years, % 35 45 31
BMI,a mean 6 SD, kg/m2 31 6 8 31 6 8 35 6 8
RCF, % 47 45 41
IHD, % 49 59 57
PAD, % 29 20 22
CVD, % 18 22 22
Predialysis, % 57 55 71
CKD due to DM, % 39 43 55
CKD due to HTN, % 35 28 22
Duration CKD,
mean 6 SD, months
44 6 44 54 6 66 60 6 75
Tobacco free, % 55 49 41
Local anesthesia, % 53 57 43
Nerve block, % 26 26 35
Fluid dilation, % 80 69 76
Mechanical dilation, % 37 35 31
Running sutures, % 94 94 96
Non-absorbable sutures, % 92 92 96
Exposed vein length,
mean 6 SD, cm
3.4 6 1.0 3.5 6 .8 3.5 6 1.0
Arteriotomy length
mean 6 SD, cm
0.9 6 0.3 0.9 6 0.3 0.8 6 0.3
BMI, Body mass index; CKD, chronic kidney disease; CVD, cerebrovascular
disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischemic heart
disease; PAD, peripheral artery disease; PRT-201, recombinant type I
pancreatic elastase; RCF, radiocephalic ﬁstula; SD, standard deviation.
aP < .05.
Table II. Number and proportion of patients with
commonly reported adverse eventsa
Event
Placebo
(n ¼ 51),
No. (%)
PRT-201
10 mg
(n ¼ 51),
No. (%)
30 mg
(n ¼ 49),
No. (%)
Any adverse event 42 (82) 39 (77) 43 (88)
AVF thrombosis 13 (26) 8 (16) 7 (14)
Steal syndrome 7 (14) 2 (4) 6 (12)
Hypoesthesia 7 (14) 6 (12) 6 (12)
AVF incision pain 5 (10) 9 (18) 9 (18)
AVF site complication 5 (10) 4 (8) 4 (8)
Peripheral edema 5 (10) 0 (0) 2 (4)
Nausea 5 (10) 1 (2) 2 (4)
Arterial stenosis 4 (8) 5 (10) 0 (0)
Paresthesia 1 (2) 1 (2) 5 (10)
Erythema 1 (2) 1 (2) 5 (10)
AVF,Arteriovenous ﬁstula; PRT-201, recombinant type I pancreatic elastase.
aTreatment of emergency adverse events occurring in at least 5% of placebo
or the combined PRT-201 treatment groups.
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tices across randomized treatment groups, with the
exception of body mass index, which was higher in the
30-mg group.
Safety. Adverse events, the most common of which are
summarized in Table II, were consistent with the medical
conditions experienced by patients with chronic kidney dis-
ease undergoing AVF creation. There were no statistically
signiﬁcant differences between the PRT-201 treatment
groups and placebo. There were no meaningful dose-related
increases in adverse events, which, as expected, were most
frequently related to the surgery and were mainly mild,
intermittent, and resolved#2weeks. Of the 15 reported cases
of steal syndrome, one in the 30-mg groupwas secondary to an
arteriovenous graft and not related to the study AVF. Nine of
the remaining 14 were graded as mild and required no
treatment. Five were graded as moderate, and two of these
were managed without intervention. The remaining three
received banding of the outﬂow vein, ligation of the distal
radial artery, and balloon angioplasty in one case each.
No signiﬁcant ﬁndings were discovered during physical
examinations or clinical laboratory testing, including chem-
istry, hematology, and coagulation panels. Pretreatment
anti-PRT-201 antibodies were detected in four patients.
Post-treatment anti-PRT-201 antibodies were detected inone placebo patient, three 10-mg patients, and two 30-mg
patients. One of the patients in the 10-mg group was previ-
ously positive at baseline. The highest titer in any positive
test was 1:2. Retests were performed at 6 months in one
placebo patient, two 10-mg patients, and one 30-mg patient
who had detectable post-treatment anti-PRT-201 anti-
bodies, and all tests were negative.
Patency. Fig 2, A displays the Kaplan-Meier analysis of
PP. The median PP time was 224 days in the placebo
group and >365 days in the PRT-201 groups. At 1 year,
45%, 54%, and 53% of placebo, 10-mg, and 30-mg patients
retained PP. The risk of PP loss was not signiﬁcantly
reduced vs placebo for 10 mg (HR, 0.69; 95% conﬁdence
interval [CI], 0.39-1.22; P ¼ .19) or 30 mg (HR, 0.67;
95% CI, 0.38-1.19; P ¼ .17).
In the placebo group, initial loss of patency was due to
thrombosis (occlusion) in 12 patients and a procedure to
restore or maintain patency in 15. In the 10-mg group,
the initial loss of patency was due to thrombosis in seven
patients and a procedure to restore or maintain patency
in 14. In the 30-mg group, the initial loss of patency was
due to thrombosis in seven patients and a procedure to
restore or maintain patency in 13. Referral to an interven-
tionalist resulting in a procedure to restore or maintain
patency was due to clinical problems with the AVF or ﬁnd-
ings identiﬁed by routine AVF surveillance.
Fig 2, B displays the Kaplan-Meier analysis of PP in
patientswith aRCF.Median patencywas 125days in the pla-
cebo group and >365 days in the PRT-201 groups. At
1 year, 31%, 50%, and 63% of placebo, 10-mg, and 30-mg pa-
tients retained PP. The risk of PP loss was nonsigniﬁcantly
reduced by 10 mg (HR, 0.59; 95% CI, 0.28-1.28; P ¼ .18)
and signiﬁcantly reduced by 30 mg (HR, 0.37; 95% CI,
0.15-.91; P ¼ .02) vs placebo. Fig 2, C displays the
Kaplan-Meier analysis of PP in patients with a BCF. At
1 year, 57%, 58%, and 46% of placebo, 10-mg, and 30-mg
Fig 2. Kaplan-Meier plots (error bars show the standard error) of unassisted primary patency (PP) in (A) all patients,
the subsets with (B) radiocephalic ﬁstulas (RCFs) and (C) brachiocephalic ﬁstulas (BCFs), and (D) all patients
excluding procedures directed at the central veins or cephalic arch.
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cebo for 10 mg (HR, 0.86; 95% CI, 0.36-2.02; P ¼ .72) or
30 mg (HR, 1.1; 95% CI, 0.49-2.46; P¼ .82). If procedures
directed at the cephalic arch or central vein stenosis were
excluded, 68% of 30-mg patients retained PP at 1 year
(HR, 0.74; 95% CI, 0.31-1.78; P ¼ .46).
Cox proportional hazard modeling was performed with
a number of demographic and intraoperative characteris-
tics. For the comparison of the 10-mg and placebo groups,
predialysis status at baseline, BCF, shorter exposed vein
length, shorter arteriotomy length, and white race were
associated with a decreased risk of PP loss. After adjusting
for baseline differences in these characteristics, the HR for
PP loss for the 10-mg group vs placebo was 0.76 (95% CI,
0.43-1.36; P ¼ .35). For the comparison of the 30-mg and
placebo groups, predialysis status at baseline, use of topical
papaverine at the time of surgery, and shorter exposed vein
length were associated with a decreased risk of PP loss. The
use of general anesthesia was associated with an increased
risk of PP loss. After adjusting for baseline differences in
these characteristics, the HR for unassisted patency loss
for the 30-mg group vs the placebo group was 0.59 (95%
CI, 0.32-1.10; P ¼ .098).In an analysis of PP loss that excluded corrective proce-
dures directed at the cephalic arch or central vein stenosis,
the HR for PP loss was 0.69 for the 10-mg group (95% CI,
0.39-1.23; P ¼ .20) and 0.52 for the 30-mg group (95%
CI, 0.28-0.97; P ¼ .04) vs placebo (Fig 2, D).
At 1 year, 77%, 81%, and 83% of placebo, 10-mg,
and 30-mg patients retained SP. The risk of SP loss was
not signiﬁcantly reduced vs placebo for 10 mg (HR,
0.79; 95% CI, 0.33-1.92; P ¼ .61) or 30 mg (HR, 0.76;
95% CI, 0.31-1.89; P ¼ .55). In the subset with RCFs,
65%, 82%, and 90% of placebo, 10-mg, and 30-mg patients
retained SP at 1 year. The risk of SP loss was not signiﬁ-
cantly different vs placebo for 10 mg (HR, 0.45; 95% CI,
0.14-1.51; P ¼ .19) or 30 mg (HR, 0.27; 95% CI, 0.06-
1.29; P ¼ .08). For patients with BCFs, 88%, 79%, and
78% of placebo, 10-mg, and 30-mg patients retained SP
at 1 year. The risk of SP loss was not signiﬁcantly different
vs placebo for 10 mg (HR, 1.71; 95% CI, 0.41-7.17; P ¼
.46) or 30 mg (HR, 2.01; 95% CI, 0.50-8.04; P ¼ .32).
Rate of procedures to restore or maintain patency
per patient per year. At least one procedure to restore or
maintain AVF patency was required in 41% of placebo pa-
tients, 36% of 10-mg patients, and 27% of 30-mg patients.
Table III. Overall rate of procedures to restore or
maintain arteriovenous ﬁstula (AVF) patency per patient
per year on study and rate excluding procedures directed
at cephalic arch (CA) or central vein (CV) stenosis
Variable
Placebo
(n ¼ 51),
mean 6 SD
PRT-201 10 mg
(n ¼ 50),
mean 6 SD Pa
PRT-201 30 mg
(n ¼ 48),
mean 6 SD Pa
All AVF 0.9 6 1.2 0.8 6 1.5 .53 0.4 6 0.7 .07
All AVF
excluding
CA/CV
0.8 6 1.2 0.7 6 1.5 .44 0.2 6 0.5 <.01
(n ¼ 24) (n ¼ 23) (n ¼ 20)
RCF 1.0 6 1.2 0.8 6 1.3 .63 0.3 6 0.6 .06
RCF
excluding
CA/CV
1.0 6 1.2 0.8 6 1.3 .63 0.3 6 0.6 .06
(n ¼ 27) (n ¼ 27) (n ¼ 28)
BCF 0.7 6 1.2 0.7 6 1.6 .72 0.4 6 0.7 .50
BCF
excluding
CA/CV
0.7 6 1.2 0.7 6 1.6 .54 0.1 6 0.4 .07
BCF, Brachiocephalic ﬁstula; PRT-201, recombinant type I pancreatic
elastase; RCF, radiocephalic ﬁstula; SD, standard deviation.
aP value vs placebo.
Table IV. Duplex Doppler-determined arteriovenous
ﬁstula (AVF) outﬂow vein lumen diameter and blood
ﬂow rate
Fistula type Placebo
PRT-201
10 mg 30 mg
All patients, No. 51 51 49
Vein lumen diameter, mm
Week 6
No. 42 43 44
Mean 6 SD 6.1 6 1.6 6.2 6 1.7 6.7 6 1.8
Month 3
No. 38 37 37
Mean 6 SD 6.7 6 1.9 7.1 6 2.2 7.3 6 1.9
AVF blood ﬂow rate, mL/min
Week 6
No. 41 39 40
Mean 6 SD 1048 6 546 991 6 678 974 6 648
Month 3
No. 35 36 35
Mean 6 SD 1084 6 709 1203 6 897 1181 6 819
RCF, No. 24 23 20
Vein lumen diameter, mm
Week 6
No. 19 22 20
Mean 6 SD 5.4 6 1.6 5.2 6 1.1 6.0 6 1.8
Month 3
No. 17 19 14
Mean 6 SD 5.6 6 2.0 6.1 6 1.4 6.7 6 1.6
AVF blood ﬂow rate, mL/min
Week 6
No. 18 18 17
Mean 6 SD 618 6 376 684 6 404 738 6 260
Month 3
No. 17 19 13
Mean 6 SD 646 6 530 790 6 622 1157 6 970
BCF, No. 27 28 29
Vein lumen diameter, mm
Week 6
No. 23 21 24
Mean 6 SD 6.6 6 1.3 7.2 6 1.6 7.2 6 1.6
Month 3
No. 21 18 23
Mean 6 SD 7.6 6 1.3 8.2 6 2.4 7.6 6 2.0
AVF blood ﬂow rate, mL/min
Week 6
No. 23 21 23
Mean 6 SD 1384 6 403 1254 6 761 1149 6 788
Month 3
No. 18 17 22
Mean 6 SD 1498 6 606 1665 6 946 1195 6 741
BCF, Brachiocephalic ﬁstula; PRT-201, recombinant type I pancreatic
elastase; RCF, radiocephalic ﬁstula; SD, standard deviation.
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maintain patency per patient per year. The data were also
examined excluding procedures directed at the cephalic
arch or a central vein stenosis, which occurred in 11 pa-
tients, 10 of whom had BCFs.
Unassisted maturation. Table IV summarizes the
vein lumen diameter and blood ﬂow data in all AVFs and in
the subsets of RCFs and BCFs. Table V summarizes the
proportion of patients with unassisted maturation at week 6
and month 3 by the NKF-KDOQI and Robbin et al
criteria. There were no statistically signiﬁcant differences in
achievement of unassisted maturation between placebo and
either active treatment group by either deﬁnition at
week 6.
The proportion with unassisted maturation at month 3
by NKF-KDOQI criteria and by the Robbin et al criteria
was signiﬁcantly greater in the 30-mg group than in the pla-
cebo group. The proportion of patients with unassisted
maturation at month 3 by the Robbin et al criteria was
signiﬁcantly greater in the 10-mg and 30-mg groups than
in the placebo group. The percentages with assisted matu-
ration at month 3 were 54%, 67%, and 70% by NKF-
KDOQI criteria and 80%, 92%, and 92% by the Robbin
et al criteria in the placebo, 10-mg, and 30-mg groups,
respectively.
Among patients with RCFs, the proportion with unas-
sisted maturation at week 6 according to the Robbin et al
criteria was signiﬁcantly greater in the 30-mg group (75%)
than in the placebo group (36%; P ¼ .01). The proportion
of patients with unassisted maturation at month 3 was
greater by NKF-KDOQI criteria and signiﬁcantly greater
by Robbin et al criteria in the 30-mg group than in theplacebo group. The percentages with assisted maturation
at month 3 were 29%, 42%, and 57% by NKF-KDOQI
criteria and 59%, 84%, and 93% by the Robbin et al criteria
in the placebo, 10-mg, and 30-mg groups, respectively, and
there were no signiﬁcant differences between groups.
Use for hemodialysis. During the course of follow-
up, 70% of patients received hemodialysis, and the per-
centages of those patients with unassisted usability were
53%, 49%, and 69% for the placebo, 10-mg, and 30-mg
groups. The percentages of patients with assisted usability
were 76%, 74%, and 83% for the placebo, 10-mg, and 30-mg
groups. None of the differences among groups were
Table V. Unassisted maturationdpercentage
Fistula type Placebo
PRT-201
10 mg Pa
PRT-201
30 mg Pa
Week 6
All types
No. 47 46 46
NKF-KDOQI,9 % 43 41 .90 50 .47
Robbin et al,19 % 60 67 .43 76 .09
RCF
No. 22 22 20
NKF-KDOQI,9 % 23 18 .48 45 .08
Robbin et al,19 % 36 50 .17 75 .01
BCF
No. 25 24 26
NKF-KDOQI,9 % 60 62 1.0 54 .78
Robbin et al,19% 80 83 1.0 77 1.0
Month 3
All types
No. 39 39 37
NKF-KDOQI,9 % 46 64 .11 70 .03
Robbin et al,19 % 67 87 .03 92 <.01
RCF
No. 17 19 14
NKF-KDOQI,9 % 24 37 .48 57 .08
Robbin et al,19 % 47 74 .17 93 <.01
BCF
No. 22 20 23
NKF-KDOQI,9 % 64 90 .07 78 .34
Robbin et al,19 % 82 100 .11 91 .41
BCF, Brachiocephalic ﬁstula; NKF-KDOQI, National Kidney Foundation
Kidney Disease Outcomes Quality Initiative; PRT-201, recombinant type I
pancreatic elastase; RCF, radiocephalic ﬁstula.
aP value vs placebo.
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subset of patients with a BCF, in which there was a
signiﬁcantly (P ¼ .03) higher percentage of patients with
unassisted usability in the 30-mg group (82%) vs the pla-
cebo group (50%).
Hemodynamically signiﬁcant lumen stenosis. At
week 6, hemodynamically signiﬁcant stenosis in the treat-
ment zone was observed in 51%, 30%, and 39% of the pla-
cebo, 10-mg, and 30-mg groups (P ¼ .048 for 10 mg vs
placebo). At month 3, hemodynamically signiﬁcant stenosis
in the treatment zone was observed in 40%, 41%, and 35%
of the placebo, 10-mg, and 30-mg groups. There were no
differences in hemodynamically signiﬁcant stenosis among
groups at month 3.
DISCUSSION
PRT-201 appeared safe and was associated with a 33%
reduction in the HR for loss of PP in the 30-mg group,
but this was not statistically signiﬁcant. The study was
powered to detect a 70% reduction in the HR in the over-
all population but was not powered to detect differences
in the subset of patients by AVF type. Treatment with
PRT-201 was associated with a signiﬁcant dose-
dependent improvement in unassisted maturation by
duplex ultrasound imaging, and patients treated with
30-mg also exhibited a trend for fewer procedures torestore or maintain patency. SP was well maintained but
not different between the groups.
In the subgroup of patients who received a RCF, 30-mg
was associated with a 63% reduction in the HR for loss of
PP and a trend for improved SP. There was also a dose-
dependent improvement in unassisted maturation assessed
by duplex ultrasound imaging.
The KDOQI Guidelines favor placement of RCFs,
which preserve vascular territory and have lower rates of
arm swelling, steal syndrome, and cephalic arch stenosis.9
However, RCFs often fail to mature, and recent literature
indicates that up to 70% lose PP #1 year after surgical cre-
ation.6,7,9 PRT-201 may have shown greater beneﬁt in
RCF because stenosis occurs predominantly in the peria-
nastomotic area, which is within the treatment zone of
PRT-201.20,21 BCFs suffer from stenosis that often mani-
fests in other locations.20,21 RCFs are also more likely to
suffer SP loss.7 For patients receiving hemodialysis, AVF
abandonment requires placement of a catheter for dialysis,
typically followed by surgical placement of a new AVF or
arteriovenous graft.
A weakness of the current study is the small number of
patients per dose group and in the subsets by ﬁstula type.
However, the results were consistent across a number of
related end points and suggest that the 30-mg dose is
more effective than the 10-mg dose and that the greatest
beneﬁts of PRT-201 treatment are observed in the subset
with RCFs. The secondary analyses were considered
exploratory and were not corrected for multiple testing.CONCLUSIONS
The results of the current study suggest that PRT-201
applied to the periadventitial surface of an AVF at the time
of surgical creation is safe and may result in improved
maturation and PP in RCFs. These results will need to
be conﬁrmed in larger, appropriately powered studies.
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at www.jvascsurg.org.INVITED COMMENTARYLewis B. Schwartz, MD, Chicago, IllThe purpose of this randomized, double-blind, placebo-
controlled clinical trial was to test the hypothesis that topically
applied human pancreatic elastase would assist maturation and
extend the patency and usefulness of dialysis-access arteriovenous
ﬁstulas (AVFs). The authors and entrepreneurs are to be congrat-
ulated for their novel and ambitious approach to the difﬁcult prob-
lem of hemodialysis access, as well as for their revealing and
aspirational trial. Dependable maturation of AVFs remains a signif-
icant clinical challenge, and to date, there are no available chemical
strategies designed to improve outﬂow vein remodeling. Should
this strategy ultimately prove efﬁcacious, it would represent a sig-
niﬁcant advance in a challenging ﬁeld of medicine.
Unfortunately, the investigators overestimated the potential
beneﬁt of their therapy, because their prespeciﬁed primary end point
of a 30% absolute improvement in 1-year primary patency was not
achieved. The negative trial results will certainly present regulatory
challenges, and further study will undoubtedly be required to secure
approval. However, because the primary patency of the control,low-dose, and high-dose groups was 45%, 54%, and 53%, respec-
tively, a positive effect of the drug appeared to be demonstrated.
Thus, the study was not a failure; it was simply underpowered to
demonstrate the 10% effect size of the experimental intervention.
Certainly, a simple maneuver, such as intraoperative elastase
application, would be clinically useful and widely applied if it reli-
ably provided a 10% increase in patency. Moreover, there were
positive trends favoring the experimental groups in all metrics,
most notably for primary patency in radiocephalic AVFs and in
“maturation-by-3-months” in all groups. Improvements in the
number and rapidity by which radiocephalic AVFs matured into
useful conduits would be welcome, indeed.
The concept that topically applied human pancreatic elastase
can assist the maturation of outﬂow veins in dialysis access AVFs
has been demonstrated. This bold trial should be viewed as a
mechanistic and clinical success and this development group
should muster the will and ﬁnancial resources to continue their
important line of research.
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